David Roblin, CEO of London-based Relation Therapeutics, on building a techbio discovery company.

The Long Run with Luke Timmerman

Ep176: David Roblin on Building a TechBio Company

Claire Mazumdar, CEO of Boston-based Bicara Therapeutics, on developing a bifunctional antibody for head and neck cancer.

Ep181: Claire Mazumdar on a Two-Pronged Attack Against Cancer

John Rinn, professor at the University of Colorado and co-founder of Lincswitch Therapeutics, on exploring long non-coding RNA.

Ep180: John Rinn on Discovering Drugs Based on Long Non-Coding RNA

Marea Therapeutics CEO Josh Lehrer and CSO Ethan Weiss on a new angle of attack against cardiovascular disease and diabetes.

Ep179: Ethan Weiss & Josh Lehrer on a New Idea for Cardiovascular Disease & Diabetes

Peyton Greenside, co-founder and CEO of BigHat Biosciences, on machine-learning guided biologic drug discovery.

Ep178: Peyton Greenside on ML-Guided Biologics Discovery

Kevin Parker, CEO of Cartography Biosciences, on finding new cancer drug targets.

Ep177: Kevin Parker on Finding Cancer Drug Targets

Andy Scharenberg, CEO of Seattle-based Umoja Biopharma, on developing in vivo CAR-T cell therapies.

Ep175: Andy Scharenberg on in vivo CAR-T cell therapies

Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.

Ep174: Najat Khan on the TechBio Movement

Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.

Ep173: Robert Blum on Building a Fully Integrated Biopharma For Muscle Disorders

Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.

Ep172: Mostafa Ronaghi on Studying Live Cells at Scale

Ciencias

"The Long Run"

Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. 

Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.